GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » EV-to-FCF

Medigen Biotechnology (ROCO:3176) EV-to-FCF : -7.36 (As of May. 16, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medigen Biotechnology's Enterprise Value is NT$4,116 Mil. Medigen Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-559 Mil. Therefore, Medigen Biotechnology's EV-to-FCF for today is -7.36.

The historical rank and industry rank for Medigen Biotechnology's EV-to-FCF or its related term are showing as below:

ROCO:3176' s EV-to-FCF Range Over the Past 10 Years
Min: -80.93   Med: -14.22   Max: 26.24
Current: -6.84

During the past 13 years, the highest EV-to-FCF of Medigen Biotechnology was 26.24. The lowest was -80.93. And the median was -14.22.

ROCO:3176's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 7.56 vs ROCO:3176: -6.84

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Medigen Biotechnology's stock price is NT$39.70. Medigen Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-4.031. Therefore, Medigen Biotechnology's PE Ratio for today is At Loss.


Medigen Biotechnology EV-to-FCF Historical Data

The historical data trend for Medigen Biotechnology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology EV-to-FCF Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.96 -11.93 26.95 -5.11 -14.57

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.58 -7.22 -14.50 -14.57 -

Competitive Comparison of Medigen Biotechnology's EV-to-FCF

For the Biotechnology subindustry, Medigen Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's EV-to-FCF falls into.



Medigen Biotechnology EV-to-FCF Calculation

Medigen Biotechnology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4116.100/-559.319
=-7.36

Medigen Biotechnology's current Enterprise Value is NT$4,116 Mil.
Medigen Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-559 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Biotechnology  (ROCO:3176) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Medigen Biotechnology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=39.70/-4.031
=At Loss

Medigen Biotechnology's share price for today is NT$39.70.
Medigen Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.031.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Medigen Biotechnology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines